Select Medical Hldgs 株価情報 (NYSE: SEM)

Select Medical Hldgs (NYSE:SEM) 株価情報

Select Medical Hldgs

Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.

Select Medical Holdings

Select Medical Holdings Corporation Common Stock

Select Medical Holdings Corp

SIEMENS HEALTHINEERS AG by Siemens Healthineers AG

Siemens Healthineers AG

Columbia Select Technology ETF

SEMrush Holdings, Inc. Class A Common Stock

SEMrush Holdings Inc

SIEM INDUSTRIES INC by Siem Industries, Inc.

Siem Industries Inc

Shares of United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) rose sharply in today's pre-market trading <a href="https://www.benzinga.com/general/travel/25/04/44826858/united-airlines-stock-takes-off-on-q1-earnings-strong-q2-forecast-fy-guidance-for-stable-and-recessionary-environments-impossible-to-predict">following first-quarter results.</a>
The company reported adjusted first-quarter earnings of 91 cents per share, beating estimates of 76 cents per share, according to Benzinga Pro. United Airlines reported first-quarter revenue of $13.21 billion, versus analyst estimates of $13.25 billion.
United also provided two sets of guidance for full-year 2025. The company anticipates full-year 2025 adjusted earnings of $11.50 to $13.50 per share in a "stable environment." United expects full-year earnings of $7 to $9 per share in a "recessionary environment."
United Airlines shares jumped 6.1% to $71.06 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) rose 101.2% to $0.4064 in pre-market trading.</li>
<li>iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) surged 73.1% to $3.34 in pre-market trading after gaining 6% on Tuesday.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 55.2% to $3.23 in pre-market.</li>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) rose 40.6% to $0.5941 in pre-market trading after jumping over 6% on Tuesday.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) jumped 30.2% to $0.3359 in pre-market trading after jumping around 9% on Tuesday.</li>
<li>Electra Battery Materials Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>) surged 20.4% to $1.30 in pre-market trading.</li>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) gained 12.3% to $155.00 in pre-market trading after the company announced a strategic alliance with AIKYA to launch ESG reporting platform, diginexESG, in Malaysia.</li>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) rose 9.3% to $2.00 in pre-market trading after dipping 11% on Tuesday.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) gained 9.1% to $17.79 in pre-market trading. Select Medical Holdings will release the financial results for its first quarter on Thursday, May 1, after the closing bell.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aura Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) fell 39% to $3.40 in pre-market trading. Aura Biosciences announced appointment of Teresa Bitetti to Board of Directors.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) fell 30.6% to $2.21 in pre-market trading after the company announced the pricing of $5.0 million registered direct offering.</li>
<li>TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) shares fell 27.3% to $0.28 in pre-market trading.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) shares dipped 25.7% to $5.00 in pre-market trading.</li>
<li>Potbelly Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) shares tumbled 25.6% to $6.00 in pre-market trading.</li>
<li>Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) shares fell 24.4% to $6.00 in pre-market trading after gaining 4% on Tuesday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) fell 24.4% to $4.40 in today's pre-market trading after gaining 3% on Tuesday.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) fell 24.2% to $6.00 in pre-market trading. Hillman Solutions will host a conference call to discuss its results for the thirteen weeks ended March 29 on Tuesday, April 29.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) dipped 6% to $127.00 in pre-market trading after the company reported a 7.6% decline in profit for the first quarter. The company posted quarterly revenue of $2.92 billion, compared to market estimates of $2.90 billion.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) declined 4.5% to $652.68 in pre-market trading as the company posted first-quarter total net sales of €7.7 billion and net income of €2.4 billion. The company said it sees second-quarter total net sales between €7.2 billion and €7.7 billion.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock"> Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AARD

ASML

AURA

BLMZ

DGNX

ELBM

HLMN

ICAD

JBHT

LRHC

OMEX

PBPB

STBX

TKNO

TRUG

Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday's.
Shares of Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) fell sharply in today's pre-market trading after the company cut <a href="https://in.benzinga.com/general/travel/25/03/44237055/delta-air-lines-cuts-q1-guidance-below-estimates-airline-stocks-fall">its first-quarter revenue and profit guidance.</a>
Delta said it now expects to deliver total revenue growth for the March quarter of 3% to 4% year-over-year, down from earlier forecasts of 7% to 9% growth. The airline also reduced its expected EPS to between 30 cents and 50 cents per share, down from previous guidance of 70 cents to $1 per share.
Delta Air Lines shares dipped 11% to $44.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>NET Power Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) shares fell 35.4% to $3.07 in pre-market trading. NET Power shares dipped around 31% on Monday after the company reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) dipped 27.4% to $12.11 in pre-market trading after the company reported fourth-quarter financial results announced the departure of CEO Dustin Moskovitz.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) fell 16.5% to $13.07 in pre-market trading after jumping 30% on Monday.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) fell 15.7% to $9.49 in today's pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>ReNew Energy Global Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) shares dipped 6.4% to $5.45 in pre-market trading.</li>
<li>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) fell 6.3% to $72.70 in pre-market trading.</li>
<li>Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) slipped 5.2% to $156.95 in pre-market trading following weak quarterly earnings.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) fell 2.2% to $17.03 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

ASAN

FERG

LZMH

NPWR

Delta Air Lines Lowers Q1 Outlook, Joins Asana, Redwire And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

RBC Capital analyst Ben Hendrix maintains Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) with a Outperform and lowers the price target from $47 to $23.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Select Medical Hldgs, Lowers Price Target to $23

WIIM

Select Medical shares are trading lower after the company reported worse-than-expected Q4 financial results.

Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.22 by 18.18 percent. This is a 50 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $1.31 billion which missed the analyst consensus estimate of $1.46 billion by 10.16 percent. This is a 20.86 percent decrease over sales of $1.66 billion the same period last year.

Earnings

Earnings Misses

Select Medical Hldgs Q4 Adj $0.18 Misses $0.22 Estimate, Sales $1.31B Miss $1.46B Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Select Medical Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) short percent of float has risen 28.95% since its last report. The company recently reported that it has 3.26 million shares sold short, which is 4.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Select Medical Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737143122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Select Medical Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Select Medical Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Select Medical Hldgs's peer group average for short interest as a percentage of float is 5.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Select Medical Hldgs?

In the current market session, Select Medical Hldgs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) share price is at $18.73, after a 0.48% increase. Moreover, over the past month, the stock decreased by 5.59%, but in the past year, spiked by 31.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_0.png" alt="Past Year Chart" />

<h3>Select Medical Hldgs P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 25.68 in the Health Care Providers &amp; Services industry, Select Medical Hldgs Inc. has a lower P/E ratio of 8.75. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736450112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Select Medical Hldgs

During the last three months, 4 analysts shared their evaluations of Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.0, a high estimate of $48.00, and a low estimate of $21.00. This current average has decreased by 6.82% from the previous average price target of $44.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1735938049_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Select Medical Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Select Medical Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Select Medical Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Select Medical Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Select Medical Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Select Medical Hldgs analyst ratings.</a>
<h2>Delving into Select Medical Hldgs's Background</h2>
Select Medical Holdings Corp is a healthcare company that operates through four main segments: critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and Concentra institutions. Critical illness recovery hospitals and rehabilitation centres are designed for patients requiring extended recovery time with medical services. These two sectors combined compose roughly half of the total revenue and include over 103 critical illness recovery hospitals and inpatient rehab facilities. The outpatient rehabilitation segment includes over 1,928 rehabilitation clinics. The Concentra segment includes over 540 occupational health centers and 147 onsite clinics. The company is headquartered in Pennsylvania, and it operates across the United States.
<h3>Select Medical Hldgs's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Select Medical Hldgs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 5.73%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Select Medical Hldgs's net margin excels beyond industry benchmarks, reaching 3.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Select Medical Hldgs's ROE excels beyond industry benchmarks, reaching 3.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Select Medical Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Select Medical Hldgs's debt-to-equity ratio is below the industry average at 2.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Select Medical Hldgs: What You Need To Know

UBS analyst A.J. Rice maintains Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) with a Neutral and lowers the price target from $40 to $21.

UBS Maintains Neutral on Select Medical Hldgs, Lowers Price Target to $21

JMP Securities initiated coverage on U.S. Physical Therapy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>), an operator outpatient physical therapy provider with more than 750 owned or managed clinics <a target="_blank" href="https://www.benzinga.com/quote/USPH" rel="noreferrer noopener">across 43 states</a>.
JMP is optimistic about the company&#8217;s unique, partnership-focused outpatient platform. Combined with its pricing strategy, acquisition capabilities, and industrial injury prevention business, it can sustain the company&#8217;s strong revenue growth, averaging 10% annually from 2021 to 2024.
The analyst has initiated with a Market Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/USPH/analyst-ratings" rel="noreferrer noopener">price target of $113</a>.
The analyst views U.S. Physical Therapy as a well-run company and a strong player in the physical therapy sector. Its unique partnership model aligns the company&#8217;s goals with its clinic partners, helping to drive growth through new clinic openings. Additionally, U.S. Physical Therapy&#8217;s expanding focus on workplace injury prevention offers a higher-margin, cost-efficient service.
While challenges like rising labor costs and Medicare reimbursement cuts persist, JMP remains optimistic about U.S. Physical Therapy&#8217;s growth potential in 2025-2026, supported by strategic acquisitions and rate negotiations.
Notably, 2025 marks the end of a five-year Medicare rate reduction plan that began in 2021. Though not factored in, any rate improvements or positive changes to Medicare rates or policies could further boost growth projections.
JMP estimates that the U.S. rehabilitation market is worth nearly $40 billion, with over 300 million physical therapy visits yearly.
The physical therapy market is highly competitive and fragmented. There are over 37,000 clinics nationwide, and no single provider holds more than 5% of the market share.
ATI Physical Therapy (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#OTC">ATIP</a>) is the only other publicly traded pure-play physical therapy company. Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>), a diversified healthcare services provider, also competes in this space through its Outpatient Rehabilitation segment, alongside its operations in long-term acute care hospitals and inpatient rehab facilities. Many of the largest physical therapy providers carry significant debt, which may limit their ability to pursue major acquisitions.
Price Action: USPH stock is trading down by 2.40% at $93.27 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42515091/home-based-health-service-provider-addus-homecare-is-well-positioned-to-grow-analyst" target="_blank" rel="noreferrer noopener">As US Faces Shortage Of Expensive Skilled Clinicians, Home-Based Health Service Provider Addus HomeCare Is Well-Positioned To Grow: Analyst</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Health Care

Initiation

General

ATIP

USPH

US Physical Therapy Positioned For Success Despite Medicare Challenges, Analyst Optimistic On Unique Growth Strategy

Select Medical Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) short percent of float has fallen 11.22% since its last report. The company recently reported that it has 1.79 million shares sold short, which is 2.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Select Medical Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732725917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Select Medical Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Select Medical Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Select Medical Hldgs's peer group average for short interest as a percentage of float is 4.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SEM) - Analyzing Select Medical Hldgs's Short Interest

<h3>Gainers</h3>
<ul>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares moved upwards by 224.5% to $9.28 during Tuesday's pre-market session. The company's market cap stands at $904.4 million. </li>
<li>Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) stock rose 23.76% to $2.5. The company's market cap stands at $226.3 million. </li>
<li>Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) shares increased by 21.07% to $22.75. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q4 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock rose 19.47% to $26.66. The market value of their outstanding shares is at $396.0 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock increased by 18.12% to $22.35. The market value of their outstanding shares is at $536.3 million. </li>
<li>Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) stock increased by 18.04% to $17.01. The market value of their outstanding shares is at $981.5 million. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares declined by 43.8% to $21.75 during Tuesday's pre-market session. The company's market cap stands at $2.8 billion. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) stock declined by 34.35% to $2.6. The company's market cap stands at $254.6 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) shares fell 20.77% to $55.01. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares decreased by 17.85% to $2.9. The market value of their outstanding shares is at $2.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) stock declined by 10.14% to $1.95. The company's market cap stands at $19.8 million. </li>
<li>Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 9.94% to $264.78. The market value of their outstanding shares is at $142.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEC

AMGN

ARWR

BTSGU

COCP

CRBU

EMBC

NGNE

PSTX

SCNI

TCMD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Select Medical shares are trading lower. The company may be moving on continued weakness after Benchmark downgraded the stock from Buy to Hold on Monday.

Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $47.75, a high estimate of $48.00, and a low estimate of $47.00. Marking an increase of 3.8%, the current average surpasses the previous average price target of $46.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732550464_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Select Medical Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Select Medical Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Select Medical Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Select Medical Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Select Medical Hldgs analyst ratings.</a>
<h2>Delving into Select Medical Hldgs's Background</h2>
Select Medical Holdings Corp is a healthcare company that operates through four main segments: critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and Concentra institutions. Critical illness recovery hospitals and rehabilitation centres are designed for patients requiring extended recovery time with medical services. These two sectors combined compose roughly half of the total revenue and include over 103 critical illness recovery hospitals and inpatient rehab facilities. The outpatient rehabilitation segment includes over 1,928 rehabilitation clinics. The Concentra segment includes over 540 occupational health centers and 147 onsite clinics. The company is headquartered in Pennsylvania, and it operates across the United States.
<h3>Breaking Down Select Medical Hldgs's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Select Medical Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.73%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Select Medical Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Select Medical Hldgs's ROE excels beyond industry benchmarks, reaching 3.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.67%, the company showcases effective utilization of assets.
Debt Management: Select Medical Hldgs's debt-to-equity ratio is below the industry average at 2.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For Select Medical Hldgs

Benchmark analyst Bill Sutherland downgrades Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) from Buy to Hold.

Downgrades

Benchmark Downgrades Select Medical Hldgs to Hold

&nbsp;Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) today announced the distribution ratio for the previously announced special stock distribution (the "Distribution") to its stockholders of its equity interest in Concentra Group Holdings Parent, Inc. ("Concentra") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>). Based on the shares of Select Medical's common stock outstanding as of November 18, 2024, the record date (the "Record Date") for the Distribution, Select Medical's stockholders will receive 0.806971 shares of Concentra's common stock for every share of Select Medical's common stock held as of the close of business on the Record Date.
The Distribution by Select Medical of the special stock distribution will be made on November 25, 2024 (the "Distribution Date") in the form of a pro rata common stock distribution to all of Select Medical's stockholders of record on the Record Date. No fractional shares of Concentra's common stock will be distributed. Instead, Select Medical's stockholders will receive cash in lieu of any fraction of a share of Concentra's common stock that they otherwise would have received. The Distribution is generally intended to qualify as tax free to Select Medical's stockholders for U.S. federal income tax purposes.
J.P. Morgan and Goldman Sachs are acting as financial advisors to Select Medical in connection with the Distribution. Dechert LLP is acting as legal advisor to Select Medical in connection with the Distribution.

Dividends

Select Medical Holdings Corporation Announces Distribution Ratio For Special Stock Distribution To Stockholders; Stockholders Will Receive 0.806971 Shares Of Concentra's Common Stock For Every Share Of Select Medical's Common Stock Held As Of The Close Of Business On The Record Date

Select intends to use the net proceeds of the Offering, together with the proceeds from the proposed new incremental term loan and cash on hand, to repay in full the term loans currently outstanding under Select's existing senior secured credit agreement, to redeem all of Select's outstanding 6.250% senior notes due 2026 and to pay fees and expenses related to the foregoing.&nbsp;

Reported Earlier, Select Medical Announces Pricing of $550M 6.250% Senior Notes Due 2032

Select Medical Holdings Corporation Declares Special Stock Distribution To Spin-Off Concentra; Estimates Stockholders Will Receive Approximately 0.806971 Shares Of Concentra's Common Stock For Every Share Of Select Medical's Common Stock Held As Of The Close Of Business On The Record Date

Offerings

Press Releases

Select Medical Holdings Corporation Announces Offering of $850 Million of Senior Notes by Select Medical Corporation

Fintech

Select Medical Holdings Corporation Announces Pricing of Offering of 6.250% Senior Notes due 2032 by Select Medical Corporation

Select Medical Holdings Corporation Announces Distribution Ratio for Special Stock Distribution to Stockholders

Mutual Funds

Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

Concentra Announces Completion of Spin-Off from Select Medical

Select Medical Holdings Corporation Completes Spin-Off of Concentra

Select Medical Holdings Corporation Closes Offering of $550 Million of 6.250% Senior Notes due 2032 by Select Medical Corporation

Select Medical Holdings Corporation to Announce Fourth Quarter and Full Year 2024 Results on Thursday, February 20, 2025

Select Medical Holdings Corporation Announces Results For Its Fourth Quarter and Year Ended December 31, 2024, Its 2025 Business Outlook, and Cash Dividend

Select Medical Holdings Corporation to Announce First Quarter 2025 Results on Thursday, May 1, 2025

Comments

Select Medical Hldgs

ニュース

パートナーシップ

ベンジンガ・グローバル